ESR2 and neoplasm: Yeh et al. demonstrated that tumor-infiltrating T lymphocytes enhance RCC invasiveness by upregulating estrogen receptor β (Erβ) expression, which suppresses DAB2IP-dependent tumor-suppressive signaling.